Literature DB >> 1683823

HLA antigen frequencies and Wegener's granulomatosis.

G E Murty1, B T Mains, D Middleton, A P Maxwell, D A Savage.   

Abstract

Previous reports of an association between HLA tissue type and Wegener's granulomatosis are contradictory. By using for the first time a highly sensitive restriction fragment-length polymorphism (RFLP) analysis in addition to standard microcytotoxicity assays, the largest series yet investigated (41 patients) was tissue typed. No association was found between any specific HLA antigen and Wegener's granulomatosis. Although the condition appears to be immunologically mediated, this study indicates that the HLA antigens do not have a major role.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683823     DOI: 10.1111/j.1365-2273.1991.tb01037.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  5 in total

1.  Immunogenetic risk factors for anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis.

Authors:  M Gencik; S Borgmann; R Zahn; E Albert; T Sitter; J T Epplen; H Fricke
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 2.  Cellular aspects of vasculitis--T cell-mediated aspects.

Authors:  M E Griffith; C D Pusey
Journal:  Springer Semin Immunopathol       Date:  2001

3.  Immunization with anti-neutrophil cytoplasmic antibody (ANCA) induces the production of mouse ANCA and perivascular lymphocyte infiltration.

Authors:  M Blank; Y Tomer; M Stein; J Kopolovic; A Wiik; P L Meroni; G Conforti; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

Review 4.  ANCA and associated diseases: immunodiagnostic and pathogenetic aspects.

Authors:  W L Gross; W H Schmitt; E Csernok
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

5.  Cell-mediated autoimmunity in patients with Wegener's granulomatosis (WG)

Authors:  B E Ballieux; S H van der Burg; E C Hagen; F J van der Woude; C J Melief; M R Daha
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.